StockpollyBeta
Get App
Popularity #1,771
XNCR · NASDAQ · Biotechnology

Xencor (XNCR)

Licenses Fc-engineered antibody technology to partners while advancing a wholly-owned bispecific pipeline.

$24.51
vs last close−0.65 (−2.59%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue59511617187033442128551
Cost of revenue6535735803354330
Gross profit−648−4114−40703041−3326251
127614761566737414798088
Research & development656357625851596254656572
121214151515171514171816
Selling & marketing0−30−300000000
General & administrative121514181515171514171816
Other expenses−651−570−580−3−3−54−3−30
Operating income−18−29−55−62−554−43−33−48−54−78−37
−616−19−58−57−524149−5115
Interest income589888877655
Interest expense06101134988757
Other non-operating income0−22104−1723−4−10−49−5746−23
Income before tax−24−13−74−67−47−53−48−31−6−4−129−22
Income tax expense0140002000200
Net income from continuing operations−24−26−74−67−47−54−49−31−6−7−129−22
Net income−24−26−73−66−46−53−48−31−6−7−129−22
EPS, basic−$0.40−$0.43−$1.11−$1.07−$0.71−$0.73−$0.66−$0.41−$0.08−$0.09−$1.71−$0.29
EPS, diluted−$0.40−$0.43−$1.11−$1.07−$0.71−$0.73−$0.66−$0.41−$0.08−$0.09−$1.71−$0.29
Weighted average shares, basic616161626473747474747576
Weighted average shares, diluted616161626473747474747576
EBITDA−15−3−61−63−35−16−37−2046−121−12
Depreciation & amortization333333333332
EBIT−18−6−64−66−38−19−40−2323−124−15